Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507464 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MEN1MAPTKMT2ACA3 | |
| SCHEMBL111957 | 0.82 | CES2 (0.36) | ALDH1A1 | |
| SCHEMBL5506924 | 0.82 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL31414602 | 0.82 | CA1 (0.40) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL19000144 | 0.82 | CA1 (0.40) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL18341100 | 0.82 | TSHR (0.40) | ALDH1A1MEN1MAPTKMT2ACA9 | |
| SCHEMBL3670713 | 0.82 | POLB (0.46) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL113475 | 0.77 | — | — | |
| SCHEMBL102976 | 0.77 | ERN1 (0.39) | ALDH1A1CA3CA6CA5ACA9 | |
| SCHEMBL2777071 | 0.77 | TNF (0.38) | ALDH1A1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036621-A | Fluorine substituted benzimidazolyl aniline compound and synthetic method and application thereof | 中茂绿能科技(西安)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-111344287-B | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4015511-A1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | CARNEGIE MELLON UNIVERSITY (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | ALDH1A1 1499/4885MEN1 848/4885MAPT 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.